Abstract：
UNASSIGNED: There are currently no guidelines on peri-arthroscopic management of immunosuppressive (IS) treatment in rheumatic disease patients.
UNASSIGNED: The purpose of this study is to characterize the rheumatic disease patient population undergoing arthroscopy, compare the incidence of postoperative complications among patients who either remained on IS perioperatively, held IS perioperatively or were not on IS at baseline, and compare the incidence of postoperative complications by rheumatic disease type, medication type, and procedure.
UNASSIGNED: We conducted a retrospective review of all arthroscopic sports medicine surgeries in patients with a rheumatic disease diagnosis at our institution over an 11-year period. Patients on IS at baseline were grouped into those who remained on IS perioperatively or held all IS before the date of their surgery. These two groups were compared to patients who were not on IS at baseline. Incidence of postoperative complications was calculated for the three cohorts and by medication class, rheumatic disease type, and procedure risk. Analysis of variance (ANOVA), chi-squared, and Fisher\'s exact tests were used to determine the statistical significance of between-group differences in postoperative complication incidence.
UNASSIGNED: We identified 1,316 rheumatic disease patients undergoing arthroscopy, with 214 of them taking IS medications at baseline. In total, 8.4% (n = 110) remained on IS perioperatively, 7.9% (n = 104) held IS perioperatively, and 83.7% (n = 1102) were not on IS at baseline. In all cohorts, seven patients experienced postoperative complications; six of whom experienced infections. Two (1.82%) occurred in patients remaining on IS perioperatively, zero infections occured in patients who held all IS, and four (0.36%) occured in patients who were not on any IS at baseline. There was no statistically significant difference in postoperative infections or complication rates among the three cohorts or further subgroups.
UNASSIGNED: The risk of postoperative complications including infectious, major, and minor complications in patients on IS at the time of arthroscopy is low and acceptable.
UNASSIGNED: The purpose of this study is to characterize the rheumatic disease patient population undergoing arthroscopy, compare the incidence of postoperative complications among patients who either remained on IS perioperatively, held IS perioperatively or were not on IS at baseline, and compare the incidence of postoperative complications by rheumatic disease type, medication type, and procedure.
UNASSIGNED: We conducted a retrospective review of all arthroscopic sports medicine surgeries in patients with a rheumatic disease diagnosis at our institution over an 11-year period. Patients on IS at baseline were grouped into those who remained on IS perioperatively or held all IS before the date of their surgery. These two groups were compared to patients who were not on IS at baseline. Incidence of postoperative complications was calculated for the three cohorts and by medication class, rheumatic disease type, and procedure risk. Analysis of variance (ANOVA), chi-squared, and Fisher\'s exact tests were used to determine the statistical significance of between-group differences in postoperative complication incidence.
UNASSIGNED: We identified 1,316 rheumatic disease patients undergoing arthroscopy, with 214 of them taking IS medications at baseline. In total, 8.4% (n = 110) remained on IS perioperatively, 7.9% (n = 104) held IS perioperatively, and 83.7% (n = 1102) were not on IS at baseline. In all cohorts, seven patients experienced postoperative complications; six of whom experienced infections. Two (1.82%) occurred in patients remaining on IS perioperatively, zero infections occured in patients who held all IS, and four (0.36%) occured in patients who were not on any IS at baseline. There was no statistically significant difference in postoperative infections or complication rates among the three cohorts or further subgroups.
UNASSIGNED: The risk of postoperative complications including infectious, major, and minor complications in patients on IS at the time of arthroscopy is low and acceptable.
摘要：
■目前尚无关于风湿性疾病患者的免疫抑制（IS）治疗的关节镜治疗指南。
■这项研究的目的是表征接受关节镜检查的风湿性疾病患者人群，比较围手术期保留IS的患者的术后并发症发生率，围手术期保持IS或基线不处于IS，并比较不同风湿病类型的术后并发症发生率，药物类型,和程序。
■我们对我院风湿性疾病诊断患者11年的所有关节镜运动医学手术进行了回顾性回顾。将基线为IS的患者分组为围手术期保持IS或在手术日期之前保持所有IS的患者。将这两组与基线时未进行IS的患者进行比较。术后并发症的发生率被计算为三个队列和药物类别，风湿性疾病类型,和程序风险。方差分析(ANOVA)，卡方，和Fisher精确检验用于确定术后并发症发生率组间差异的统计学意义。
■我们确定了1,316例接受关节镜检查的风湿性疾病患者，其中214人在基线时服用IS药物。总的来说,8.4%(n=110)仍在围手术期，7.9%(n=104)的患者围手术期，和83.7%(n=1102)在基线时没有IS。在所有队列中，7例患者出现术后并发症;其中6例出现感染.2例（1.82%）发生在保留在围手术期的患者中，在持有所有IS的患者中发生零感染，4例(0.36%)发生在基线时没有任何IS的患者中.在三个队列或其他亚组之间，术后感染或并发症发生率没有统计学上的显着差异。
■术后并发症的风险，包括感染，major,关节镜检查时IS患者的轻微并发症较低且可接受。
■这项研究的目的是表征接受关节镜检查的风湿性疾病患者人群，比较围手术期保留IS的患者的术后并发症发生率，围手术期保持IS或基线不处于IS，并比较不同风湿病类型的术后并发症发生率，药物类型,和程序。
■我们对我院风湿性疾病诊断患者11年的所有关节镜运动医学手术进行了回顾性回顾。将基线为IS的患者分组为围手术期保持IS或在手术日期之前保持所有IS的患者。将这两组与基线时未进行IS的患者进行比较。术后并发症的发生率被计算为三个队列和药物类别，风湿性疾病类型,和程序风险。方差分析(ANOVA)，卡方，和Fisher精确检验用于确定术后并发症发生率组间差异的统计学意义。
■我们确定了1,316例接受关节镜检查的风湿性疾病患者，其中214人在基线时服用IS药物。总的来说,8.4%(n=110)仍在围手术期，7.9%(n=104)的患者围手术期，和83.7%(n=1102)在基线时没有IS。在所有队列中，7例患者出现术后并发症;其中6例出现感染.2例（1.82%）发生在保留在围手术期的患者中，在持有所有IS的患者中发生零感染，4例(0.36%)发生在基线时没有任何IS的患者中.在三个队列或其他亚组之间，术后感染或并发症发生率没有统计学上的显着差异。
■术后并发症的风险，包括感染，major,关节镜检查时IS患者的轻微并发症较低且可接受。
